Company: CDT
Filing Date: 2025-07-08
Form Type: DEF 14A
Source: 0001641172-25-018242
Chunk: 25

Company: CDT Equity Inc.
Filing Date: 2025-07-08
Form: DEF 14A
Chunk 25
---
 stock price of $284 on the date of grant.                                                                                      |
| (3) | Reflects the grant date fair value of stock option                                                                                  
 awards for the applicable year computed in accordance with FASB ASC Topic 718 Compensation – Stock Compensation. See Note 11        
 to the consolidated financial statements included in our Annual Report filed on Form 10-K for the year ended December 31, 2024, for 
 a discussion of the relevant assumptions used in calculating the grant date fair value pursuant to FASB ASC Topic 718. As required  
 by SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions. Our named  
 executive officers will only realize compensation to the extent the trading price of our common stock is greater than the exercise  
 price of such stock options.                                                                                                        |
| (4) | The amounts shown for 2024 represent 401(k) matching                                                                                
 contributions of $16,732 and $3,300 for Mr. Bligh and Mr. Sragovicz, respectively.                                                  |
| (5) | On April 12, 2025, David Tapolczay resigned from his                                                                                
 position as Chief Executive Officer and as a member of the Board. Dr. Andrew Regan succeed Mr. Tapolczay as the Company’s Chief     
 Executive Officer.                                                                                                                  |
| (6) | For Mr. Sragovicz, includes severance benefits of continued                                                                         
 payment of his base salary, and subsidized health insurance premiums, for a period of four months after the effective date of his   
 resignation.                                                                                                                        |

| 16 |

Compensation Adjustments for 2024

Annual Base Salaries

We provide a base salary to retain and attract key executive talent and to align our compensation with market practices. Base salaries are reviewed and established by the Compensation Committee and the Board on a competitive basis each year to align with market levels.

In 2024, the Board (i) increased Dr. Tapolczay’s base salary by 3%, and (ii) increased Mr. Bligh’s base salary by £60,000 to compensate for his additional duties as interim Chief Financial Officer.

Equity Awards

The Compensation Committee believes that a competitive long-term incentive program is an important component of the compensation of our named executive officers because it: (i) enhances the retentive value of our compensation; (ii) rewards executives for increasing our stock price and developing long-term value; and (iii) provides executives